Floatz logo

Zanidatamab

HER2-Positive Advanced Biliary Tract Cancer

monoclonal_antibodyDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

84 Active assets in the HER2-Positive Advanced Biliary Tract Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Merck Sharp & Dohme LLC
Phase 3BB
Epirubicin
Merck Sharp & Dohme LLC
Phase 3BB
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3BB
Capecitabine
Zhejiang Cancer Hospital
Phase 2BB
FLUOROURACILUM
Shenzhen Xinhe Biomedical
Phase 2BB

View all 50 →

Same molecule, other indications

Zanidatamab is also rated in:

HER2 positive breast carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
HER2 Low Breast CarcinomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →